• Golf simulation producer TruGolf Holdings has engaged wholly owned subsidiary Polymath to migrate the capitalization table of its TruGolf Links franchise business onto Polymesh, a blockchain designed for regulated digital securities.
• The agreement marks the first internal technology deployment since TruGolf completed its acquisition of Polymath on October 8, 2026, as the combined company seeks to pair TruGolf’s established golf simulation business with Polymath’s digital securities infrastructure.
• TruGolf Links’ Regional Developers in New Jersey, New York, and Illinois represent more than 100 future locations, as the network scales toward 221+ committed locations.
• The tokenized ownership infrastructure is intended to support investor onboarding and compliance controls as the franchise network expands.
• TruGolf and Polymath are developing an equipment leasing program and fractional franchise ownership opportunities for qualified franchisees, with initial rollout targeted for the first quarter of 2027.

TruGolf Holdings (NASDAQ: TRUG), a producer of advanced golf simulation systems for home or entertainment venues, has engaged its newly acquired subsidiary Polymath to put the ownership records of its indoor golf franchise business onto a blockchain-based securities platform, marking the first technology deployment announced since TruGolf and Polymath officially combined October 8, 2026.

Under an intercompany agreement announced October 14, TruGolf Links Franchising LLC will work with Polymath Research Inc. to migrate its capitalization table, or cap table, onto Polymesh, a public, permissioned blockchain designed for regulated digital assets. The system is intended to incorporate investor identity verification and transfer restrictions into the digital representation of equity ownership (https://ibn.fm/Ikbrm).

The agreement follows TruGolf’s completion of its acquisition of Polymath on October 8. It provides an initial practical application for the tokenization business within TruGolf’s existing operations, rather than an external customer deployment.

The companies are also developing an equipment leasing program and fractional franchise ownership opportunities for qualified franchisees. Initial rollout is targeted for the first quarter of 2027.

The development links two different business models: TruGolf’s golf simulation hardware and software operations, and Polymath’s technology for issuing and managing tokenized securities. 

TruGolf Links uses a Regional Developer model in which operators acquire exclusive territories in markets with populations of one million or more. The company opened its flagship location at Plaza at Cherry Hill in New Jersey in July. TruGolf Links’ Regional Developers in New Jersey, New York, and Illinois represent more than 100 future locations, as the network scales toward 221+ committed locations. These are planned locations represented by developer commitments, not operating facilities.

As a franchise network grows, keeping ownership records accurate and managing transfers can become more complex. Polymath’s planned cap-table migration is intended to provide a centralized, real-time record of equity ownership while embedding identity checks and restrictions on transfers into the tokenization infrastructure. The structure is designed to help support compliance with applicable securities laws. 

In the company’s announcement of the engagement, TruGolf Links President Nate Larsen described the project as a next step in applying technology not only to how golf is played, but also to how the underlying business is owned. 

“TruGolf has spent more than forty years proving the game belongs indoors. Every bay we open runs on TruGolf’s trusted simulation technology. Now the business behind those bays runs on technology built for where we believe capital markets are heading. We built the future of how golf is played. This is the next chapter: how it’s owned,” Larsen said.

Natalie Hirsch, TruGolf’s chief financial officer and chief operating officer, and Polymath’s chief executive officer, characterized the deployment as an early example of pairing an operating business with digital securities infrastructure.

TruGolf has operated in golf technology for more than four decades. Its business includes indoor golf simulation systems, software and the E6 platform, which supports digital golf experiences and competition. TruGolf Links offers indoor golf facilities with memberships, leagues, lessons, tournaments and private events. Its expansion model depends on franchise development and the ability to attract operators who can finance and run additional locations.

Founded in 2017, Polymath developed the ST-20 security token standard and launched Polymesh in 2021. Its technology is designed to support the issuance and administration of digital securities, with identity and compliance functions built into the network.

For more information, visit the company’s website at www.TruGolf.com.

NOTE TO INVESTORS: The latest news and updates relating to TRUG are available in the company’s newsroom at https://ibn.fm/TRUG

Important Notice

No securities are currently being offered pursuant to this announcement. Any future offering, including any equipment leasing or fractional franchise ownership opportunity, will be made only pursuant to applicable offering documents and in accordance with applicable securities laws and regulations. This release is not an offer to sell or a solicitation of an offer to buy any security, and is not a recommendation with respect to any investment.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, as well as forward-looking information within the meaning of applicable securities laws. Forward-looking statements are statements that are not historical facts and include statements regarding beliefs, plans, expectations, intentions, estimates, projections, or assumptions regarding future events or performance.

Forward-looking statements in this press release include, but are not limited to, statements regarding: the services to be provided by Polymath to TruGolf Links and the anticipated benefits of the agreement; the migration of TruGolf Links’ capitalization table to tokenized form; the anticipated development and timing of TruGolf Links’ equipment leasing program and fractional franchise ownership opportunities; the expected growth of the TruGolf Links franchise network; and the anticipated benefits of TruGolf’s acquisition of Polymath.

Forward-looking statements are generally identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “projects,” “estimates,” “may,” “will,” “would,” “could,” “should,” and similar expressions or the negative thereof. These statements are based on current expectations, assumptions, and estimates of management as of the date of this press release and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or developments to differ materially from those expressed or implied by such forward-looking statements.

Factors that could cause actual results to differ materially from those contemplated by the forward-looking statements include, among others: TruGolf’s ability to successfully integrate Polymath’s business and realize the anticipated benefits of the acquisition; TruGolf Links’ ability to open committed locations; risks related to digital assets, tokenized securities, and token-related initiatives; changes in market conditions; changes in applicable laws or regulations; competitive pressures; general economic and business conditions; and other risks and uncertainties described from time to time in TruGolf’s filings with the Securities and Exchange Commission.

Although management believes that the assumptions and expectations reflected in the forward-looking statements are reasonable as of the date hereof, no assurance can be given that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and TruGolf undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.

• Lahontan CEO walked through the steps that keep the company’s 2027 construction target on track during recent interview.
• Lahontan recently announced a definitive agreement to acquire Emergent Metals, which would give it 100% of West Santa Fe, eliminates approximately $1.73 million in future payments, and ends 1% net smelter return royalties on West Santa Fe and 27 York claims at Santa Fe, and adds adjoining New York Canyon project.
• Permitting work has been under way for the past three and a half years and an updated preliminary economic assessment is due imminently.

A gold price above $4,100 an ounce does little for a developer that cannot say when it will build, which makes the timeline the real story for companies still short of production. Dual-listed on the TSX Venture Exchange and OTCQB, Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is telling that story with a date attached, and in a recent CEO.CA interview, founder and CEO Kimberly Ann walked through the steps that keep its 2027 construction target on track. The company is a Nevada-focused mine developer advancing four gold and silver projects in the Walker Lane, led by the planned restart of the past-producing Santa Fe Mine.

Gold is holding at historically high levels while trading well off its peak. Spot gold was at $4,183.13 an ounce in early October, after hitting what CNBC reported as a two-month low. Gold’s record remains the $5,597.23 reached on January 29, 2026, and CNBC reported that traders were pricing an 82% probability of a Federal Reserve rate increase in December.

That backdrop matters for Lahontan because of the assumptions beneath the numbers. The company’s updated mineral resource estimate (“MRE”), announced August 17, outlined 1,195,000 gold-equivalent ounces in the indicated category and 1,190,000 in the inferred category, all pit constrained, a 22% increase over the 2024 estimate. It was calculated at $3,250 gold, more than $900 below last week’s spot price. Santa Fe previously produced 359,202 ounces of gold and 702,067 ounces of silver between 1988 and 1995 from open pits with heap-leach processing.

The CEO.CA conversation opened with the transaction. On September 16, Lahontan announced a definitive agreement to acquire Emergent Metals Corp., a deal that gives it 100% of West Santa Fe, eliminates approximately $1.73 million in future payments, ends 1% net smelter return royalties on West Santa Fe and 27 York claims at Santa Fe, and adds the adjoining New York Canyon project. Completion remains subject to Emergent shareholders, with a vote expected in November, court and TSX Venture Exchange approvals.

“We are looking at strategic opportunities to grow our land package on a low-cost basis,” Ann stated. “This transaction is about 4% dilution to our shareholders,” observing that the ground around the company’s existing pits drove the timing. “My team has found so much more mineralization that it was going to be problematic later and needing a layback for those pits,” she continued. “So, I wanted to pull the trigger earlier than later.”

Regarding permitting, Ann said the work has been under way for three and a half years and that an updated preliminary economic assessment is due “in the next couple weeks.” She described it as an engineering document not a promotional one, looking at “where are we putting the pads? How much dust we’re kicking up? How much rock we’re moving?”  Those details are required, she explained, “because it’s the last component of our application for a mine permit . . . [which] will set us up for having our permit in Q2 of next year.” Lahontan’s website lists Nevada state permitting as in progress, a federal Mine Plan of Operations as the next step and construction targeted for 2027.

At West Santa Fe, where Lahontan mobilized a drill rig last month for approximately 3,500 meters of drilling in 20 holes, Ann said the appeal is simple: “It’s all oxide. It starts at the surface. It’s 13 kilometers away.” She outlined two options, trucking material to Santa Fe for crushing and processing with “virtually no capex” or adding leach pads on site if drilling outlines enough ounces. Baseline studies began about nine months ago, she noted, “because we know it’s going to take two years in baseline studies.” The company is targeting a maiden resource by year-end.

Ann also addressed the build. Lahontan recently added a vice president of exploration, a senior mine engineer and an investor relations and business development lead, and named a new chief financial officer. The 2024 economic study estimated preproduction capital at $135.1 million, including a 20% contingency, and Ann said she does not expect the updated figure to rise much. The company plans to fund roughly 80% with debt and the rest with equity. “A straight debt deal is really advantageous when your payback is less than a year and a half,” she observed.

“Next year we’re going to be pouring gold,” Ann continued, adding that the company will tell investors if a timeline changes. “I like full transparency to shareholders because nobody likes it when they hear silence for six months,” she said.

For more information, visit the company’s website at www.LahontanGoldCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the company’s newsroom at ibn.fm/LGCXF

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Powermax Minerals, focused on rare earth element projects in North America, has entered into a three-year option agreement to acquire a 100% interest in the Melba North Property
• The property is underlain by the Clay-Howells Alkalic Rock Complex that is interpreted as a center characterized by LREE-dominant, magnetite-associated and carbonatite-related REE mineralization
• A 2025 assessment report on the Clay-Howells claim, which included claims listed on the Melba North option schedule, documented 49 samples that returned more than 0.17% total rare earth element oxides (“TREO”)
• The Melba North Property is adjacent to Powermax’s Hopkins REE property, where the company has, using a desktop study, identified priority areas for future field validation; however, mineralization continuity between the two sites has not yet been established

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company focused on rare earth element projects in North America, recently entered into a three-year option agreement with Gravel Ridge Resources Ltd. and 1544230 Ontario Inc. The agreement grants Powermax an option to acquire a 100% interest in the Melba North property (https://ibn.fm/YvKri).

Located in the Clay-Howells townships area of northern Ontario, the Melba North Property is adjacent to Powermax’s Hopkins REE property. It consists of 10 unpatented mining claims comprising 160 cells and covering approximately 3,360 hectares. Both the Melba North and the Hopkins are underlain by the Clay-Howells Alkalic Rock Complex, a Late Precambrian alkalic intrusive complex. Interpretations of data from the complex describe a structurally emplaced, multi-phase alkaline-carbonatite intrusive center characterized by LREE-dominant, magnetite-associated and carbonatite-related REE mineralization (https://ibn.fm/2ai8M). (Note: Although Hopkins and Melba North are adjacent sites, mineralization continuity between them has not yet been established.)

Claims listed in the Melba North option schedule were covered in a November 2025 assessment work report by Laurentia Exploration Inc. for Argyle Resources Corp. The report documented seven heli-portable BTW size drill holes totaling 1,983 meters on the Clay-Howells claim. “Across the selected samples reported, 49 returned more than 0.17% TREO (total rare earth element oxides), including 20 above 0.30% TREO and six above 0.50% TREO. The highest reported sample interval was 0.76% TREO over 0.60 m,” reads Powermax’s announcement of the agreement.

The company plans to include Melba North in its current Hopkins-area exploration work and wants to confirm whether a permit issued on September 2, 2025, remains valid and covers the planned drilling before mobilization. In addition to combining the exploration work at the two adjacent properties, Powermax intends to integrate the historical drill database with mapping, sampling, and geophysical data to “refine targets and assess follow-up drilling.”

“Melba North adds an important land position beside Hopkins and lets us evaluate the two areas within a coordinated exploration framework,” commented Paul Gorman, CEO of Powermax. “We will integrate the 2025 drilling data with our current field work and evaluate suitable targets for follow-up drilling, subject to permit conditions and regulatory approvals.”

The Melba North Property option agreement comes a few months after Powermax announced the option to acquire the Hopkins Rare Earths Project comprising 13 mineral claims that cover about 6,145 hectares (https://ibn.fm/DgcrA). The company later announced it had received a desktop study for the project, which evaluated publicly available datasets to assess REE prospectivity. The study identified multiple priority targets, providing Powermax with a clear, focused path forward for field validation (https://ibn.fm/2ai8M).

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

• Versus Systems is a leading provider of gamification and audience engagement technology, with a product ecosystem that includes games, digital platforms, and physical collectibles.
• The company enhances how audiences interact with content both physically and digitally, and lets brands, teams, and creators add interactive and engaging elements directly into fan experiences.
• Versus Systems has worked with significant brands such as the NFL, NHL, FIFA, MLS, and UFC, engaging more than 10 million customers.

Gaining consumer and viewer attention is growing more difficult than ever due to increasingly crowded digital and physical advertising landscapes. Even if a brand is able to capture attention, holding onto it is a recognized challenge.

Versus Systems (NASDAQ: VS) uses a unique and effective approach to address this issue, using gamification and powerful audience engagement strategies to maximize how audiences interact with content both on their devices and in person. The company operates a platform that lets brands, sports teams, content creators, and other businesses, put games and real-world rewards inside their content to help turn passive viewers into active participants. Versus Systems also has a patented earned-rewards system that operates across web, mobile, and in-venue formats, and supports both measurable brand interaction and audience participation, without requiring significant development.

Versus’ product ecosystem is designed to integrate gamification, rewards, and engagement, and includes Winfinite, Filter Fan Cam, and Drinkfinger.

Winfinite is Versus’ core gamified marketing platform, which offers a library of customized web-based games that you can deploy across your digital channels or add into your live events. The available options include sports, trivia, arcade, and puzzle games, and they’re designed to be broadly accessible and encourage repeat participation.

Filter Fan Cam is an in-venue AR fan engagement product that lets people in the audience of your event see themselves on the big screen with real-time visual enhancements like filters and overlays. The product is custom-built to leverage facial recognition technology, and applies filters and/or overlays over camera footage to create fun and interactive moments. These moments may be displayed in the venue itself, or even included in coverage of the event.

Versus has also partnered with Drinkfinger, an independent company that offers QR-enabled and collectible beverage carriers. The carriers, sporting an iconic “#1” finger shape, not only make it easier to transport drinks, but also puts branded designs right into a fan’s hand. Through Drinkfinger, fans can scan a QR code on a beverage carrier to access games, promotional offers, and event-related content on their phones.

Versus Systems’ products have been used across global markets, including the UK, Mexico, Japan, and others, and it has worked with major brands like the NFL, NHL, MLS, FIFA, and the UFC. It has also engaged more than 10 million customers and deployed its technology across thousands of events.

The team at Versus Systems is made up of executives with decades of experience in finance, media, technology, and led by CEO Luis Goldner and CFO Brian Goldenberg, C.P.A. Goldner brings over 16 years of executive management experience across the tech, media, and gaming industries, and Goldenberg has more than 25 years of financial and operational leadership experience, and has served as CFO, COO, and CCO at multiple investment management firms.

About Versus Systems Inc. (NASDAQ: VS)

Versus Systems is a technology company that looks to enhance how audiences interact with brands and engage with content in both digital and physical environments by using audience engagement and gamification. It lets brands, sports teams, creators, and other businesses add interactive elements into their content and experiences, and is trusted by many of the world’s leading brands.

For more information, visit the Versus Systems website at https://www.versussystems.com.

NOTE TO INVESTORS: The latest news and updates relating to VS are available in the company’s newsroom at https://ibn.fm/VSI

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertisements.

• Adaptogenics is pursuing three complementary opportunities across pharmaceutical-quality peptide supply, proprietary therapeutics and next-generation delivery technologies.
• Its planned supply network could generate commercial revenue while supporting therapeutic development through external manufacturing and laboratory partners.
• The company is targeting metabolic health, muscle preservation, mitochondrial function, recovery and healthy ageing through proprietary peptide and small-molecule therapeutics.
• CEO Dr. J. David Warren brings a scientific record that includes 17 issued patents, while President Antoun Nabhan brings experience spanning more than $2 billion in healthcare transactions and two Nasdaq IPO processes.
• Adaptogenics is evaluating non-injectable and targeted local delivery technologies that could improve peptide utility, generate intellectual property and expand commercial applications.

Adaptogenics (CSE: ADPT) is building a healthcare company focused on opportunities across the rapidly evolving peptide sector, combining proprietary therapeutic development, pharmaceutical-quality supply infrastructure and innovative drug delivery technologies.

As demand for solutions addressing metabolic health, muscle preservation, recovery and healthy ageing continues to grow, Adaptogenics is positioning itself to address significant healthcare challenges while pursuing opportunities in the expanding market for high-quality peptide development and supply.

The company’s strategy combines experienced pharmaceutical leadership, scientific innovation and a capital-efficient business model designed to create both near-term commercial opportunities and long-term value through proprietary therapeutic assets.

Three Opportunities Driving Adaptogenics’ Strategy

1. Pharmaceutical-Quality Peptide Supply

The growing interest in peptide-based healthcare is creating opportunities for reliable manufacturing, independent quality verification and transparent supply chains.

Adaptogenics is working toward establishing a U.S.-based GMP manufacturing and independently verified peptide supply network, supported by qualified manufacturing partners, analytical laboratories and documented chain-of-custody procedures.

The company’s objective is to develop a trusted supply model that can serve appropriate research, pharmaceutical and healthcare customers, subject to applicable regulatory requirements.

Rather than investing heavily in manufacturing facilities, Adaptogenics intends to leverage qualified external partners while building its own standards, development capabilities and commercial relationships.

This strategy could establish a foundation for future commercial revenue while supporting the company’s proprietary therapeutic development programs.

2. Proprietary Peptide and Small Molecule Therapeutics

Adaptogenics is pursuing the development of proprietary peptide and small molecule therapeutics targeting some of the most important challenges in modern healthcare.

Key areas of scientific and commercial interest include:

• Metabolic Health: Exploring therapeutic approaches relevant to obesity, metabolic dysfunction and the growing use of GLP-1 treatments.
• Muscle Preservation and Physical Function: Pursuing opportunities to address muscle loss, reduced strength and functional decline associated with ageing and metabolic conditions.
• Mitochondrial Health: Investigating peptide approaches targeting cellular energy and mitochondrial function.
• Recovery and Tissue Repair: Evaluating therapeutic candidates and delivery strategies that could address limitations in existing approaches to healing and recovery.
• Healthy Ageing: Exploring opportunities to preserve physical function and improve health outcomes as populations age.

The company’s objective is to generate differentiated intellectual property, advance promising candidates through meaningful scientific milestones and establish opportunities for future pharmaceutical partnerships, licensing and commercialization.

3. Next-Generation Peptide Delivery Technologies

Many peptide therapeutics face challenges related to administration, stability and absorption.

Adaptogenics is evaluating delivery technologies designed to address these limitations, including non-injectable approaches and targeted local delivery systems.

Successful development could improve the potential utility of selected peptide therapeutics, create additional intellectual property and expand their commercial applications.

The company’s approach is to select delivery technologies based on measurable performance advantages rather than pursuing a single delivery method across every molecule.

Leadership Built for Execution

Dr. J. David Warren, PhD – Chief Executive Officer

Dr. Warren is an accomplished medicinal and peptide chemist with extensive experience in therapeutic research and development.

His scientific background includes:

• 17 issued U.S. and international patents.
• More than 53 scientific publications and book chapters.
• Research experience at Weill Cornell Medicine.
• Foundational research involving the mitochondrial peptide SS-31 and its interaction with cardiolipin.

SS-31 was subsequently developed as elamipretide, marketed as Forzinity, which received FDA accelerated approval in 2025 for Barth syndrome. The product was developed by another company and is not an Adaptogenics asset.

Dr. Warren’s expertise in peptide chemistry, molecular design and drug development provides scientific leadership for Adaptogenics’ therapeutic development strategy.

Antoun Nabhan – President

Mr. Nabhan brings extensive healthcare transaction, financing and corporate development experience to Adaptogenics.

His background includes:

• More than US$2 billion in healthcare transactions.
• Experience supporting two Nasdaq IPO processes.
• Senior leadership and corporate development experience across pharmaceutical and biotechnology companies.
• Experience identifying, financing and advancing healthcare opportunities.

His expertise supports the company’s strategic partnerships, capital formation and long-term corporate development objectives.

Building Momentum

Adaptogenics is entering an important phase of its corporate development, with a strategy focused on advancing proprietary therapeutics, establishing pharmaceutical-quality supply capabilities and building a foundation for commercial growth.

Key priorities and anticipated milestones include:

• U.S. Pharmaceutical-Quality Supply: Establishing a U.S.-based GMP manufacturing and independently verified peptide supply network, creating a foundation for potential commercial opportunities and strategic healthcare partnerships.
• Proprietary Therapeutic Pipeline: Advancing peptide and small molecule development programs targeting high-value opportunities in metabolic health, muscle preservation, recovery and healthy ageing.
• Next-Generation Delivery: Progressing formulation and delivery research aimed at overcoming limitations in peptide administration, stability and bioavailability.
• Scientific Validation and Intellectual Property: Generating experimental data, advancing proprietary molecular designs and identifying opportunities to strengthen patent protection.
• Commercial Expansion: Developing relationships with healthcare providers, pharmacies and strategic distribution partners to identify compliant routes to market.
• Strategic Growth and Capital Markets: Building institutional relationships and positioning the company for its next phase of development and potential growth financing.

Together, these initiatives are intended to position Adaptogenics to advance from foundational research and infrastructure development toward proprietary therapeutic assets, potential commercial opportunities and measurable value creation.

The Long-Term Vision

Adaptogenics aims to build a substantial healthcare company operating across complementary segments of the peptide industry.

The company’s long-term vision combines:

• Commercial Opportunity: Establishing pharmaceutical-quality peptide supply capabilities and healthcare distribution relationships that could support future revenue generation.
• Scientific Innovation: Developing proprietary peptide and small molecule therapeutics addressing significant healthcare needs.
• Intellectual Property: Creating and securing differentiated molecular, formulation and delivery technologies with potential commercial value.
• Strategic Partnerships: Working with pharmaceutical companies, research institutions, qualified manufacturers and healthcare organizations to accelerate development and expand market opportunities.
• Scalable Growth: Building a capital-efficient business that can expand its therapeutic portfolio and commercial capabilities without requiring ownership of every manufacturing or research facility.

Adaptogenics believes the convergence of peptide innovation, advances in metabolic medicine and growing global demand for healthier ageing creates an opportunity for companies capable of combining scientific expertise with pharmaceutical-quality development and commercial execution.

The company’s ambition is to participate in this evolving healthcare landscape by building proprietary assets, advancing innovative therapies and establishing the infrastructure to support long-term growth.

NOTE TO INVESTORS: The latest news and updates relating to ADPT are available in the company’s newsroom at https://ibn.fm/ADPT

• Orthopedic care is increasingly focused not only on relieving symptoms, but on delivering durable outcomes that can stand up over time.
• That shift is creating greater interest in regenerative approaches designed to restore damaged tissue rather than simply address the immediate effects of injury.
• Regentis Biomaterials is advancing this approach with GelrinC, a degradable hydrogel implant designed to support the regeneration of durable cartilage in the knee.

Orthopedic medicine has long focused on relieving pain and restoring mobility. Increasingly, though, the question is: How well will the result hold up over time?

That question is particularly important in cartilage repair. Unlike many other tissues, cartilage has limited natural capacity to heal itself. The goal is to create an environment where damaged tissue can be repaired in a way that delivers meaningful and sustained results.

This emphasis on durability is helping drive interest in regenerative medicine, including approaches designed to replace damaged tissue with newly regenerated tissue rather than relying solely on temporary symptom management.

One company pursuing this approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing tissue repair solutions with an initial focus on orthopedic applications. Its technology is built around the Gelrin platform, which uses degradable hydrogel implants to support the body’s natural regenerative processes.

The company’s lead product, GelrinC, is a cell-free, off-the-shelf hydrogel that is cured as a temporary implant into the knee. Rather than remaining permanently in the body, GelrinC gradually resorbs. As it retreats, newly generated cartilage fills the space, creating a controlled process intended to restore the damaged area with new tissue.

According to Regentis, the implant is designed to be fully resorbed within approximately six to nine months, at which point new cartilage has covered the treated lesion.

The procedure is also designed with practicality in mind. Regentis says GelrinC can be implanted in approximately 10 minutes, fits into existing surgical workflows and is associated with a short recovery period of approximately two weeks. Its off-the-shelf design is intended to further simplify adoption while potentially offering a substantial cost advantage compared with certain alternative treatments.

Importantly, GelrinC has already achieved a CE mark in Europe, giving Regentis a commercial pathway in that market while the company continues advancing the product in the United States.

Regentis has conducted a Pilot/Phase II study of GelrinC, with results indicating 100% greater pain improvement compared with the traditional microfracture procedure. The company is now conducting its U.S. pivotal Phase III clinical study while preparing for the Premarket Approval (“PMA”) process with the U.S. Food and Drug Administration.

Durability is also something Regentis measures directly. To assess the quality of the cartilage GelrinC helps regenerate, the company uses MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue), a validated MRI-based score that evaluates the quantity and quality of repair tissue. Regentis says it is the first company to extensively use MOCART as an endpoint in a clinical study and to have the FDA’s acceptance of this approach. Long-term follow-up results from the Phase II study, published in the peer-reviewed journal Cartilage, showed a mean MOCART score of 88.8 out of 100 at 24 months, including 86.8 for chondral lesions and 94.1 for osteochondral lesions. According to the company, the data indicate that two years after treatment, the repaired cartilage appears very close to normal healthy cartilage.

That clinical progress is unfolding alongside an expanding commercialization effort. In a recent BioMedWire podcast appearance, Regentis CEO Dr. Ehud Geller discussed the company’s technology, market opportunity and priorities for the remainder of 2026.

Among those priorities is completing enrollment of the remaining patients in the company’s pivotal U.S. study while continuing to advance commercialization efforts, particularly in Europe, where Regentis already has authorization to market and sell GelrinC(R).

Those milestones provide an important backdrop to the company’s larger vision. Regentis is not simply seeking to develop another way of treating knee cartilage damage; it is pursuing a regenerative approach built around the idea that the quality of a repair should ultimately be measured by how well it lasts.

As orthopedic medicine continues to evolve, that may prove to be one of the most important measures of progress: not simply whether a treatment can provide relief today, but whether it can help patients maintain that improvement well into the future.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of (NYSE American: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

• Nanox is working to make advanced medical imaging more accessible through digital 3D tomosynthesis technology designed to enhance visualization beyond conventional X-rays.
• Its Nanox.ARC platform combines imaging hardware with cloud-based infrastructure, while the company’s broader services support image interpretation and clinical workflows.
• By connecting image acquisition with remote radiology expertise and AI-powered analysis, Nanox aims to support healthcare providers’ imaging and interpretation workflows more efficiently.

Access to medical imaging remains an important consideration for healthcare systems, particularly in underserved regions where equipment, infrastructure and trained personnel may be limited. While conventional X-rays play an essential role in diagnostic care, their two-dimensional images can make certain anatomical details more difficult to distinguish when structures overlap. In some healthcare settings, rising imaging volumes and radiologist workforce constraints can also place pressure on diagnostic services. These challenges underscore the importance of developing imaging technologies that can complement existing diagnostic approaches while integrating into established clinical environments and workflows.

Nano-X Imaging (NASDAQ: NNOX) is approaching that problem from a different direction. Nanox is assembling an integrated platform intended to extend medical imaging into outpatient facilities, clinics and other settings where conventional advanced imaging infrastructure may not be available.

At the center of this effort is Nanox.ARC, an FDA-cleared multi-source digital tomosynthesis system that incorporates the company’s proprietary digital X-ray source technology. The system is designed to produce 3D tomosynthesis images for its cleared intended uses and to support imaging in a range of clinical settings.

That matters because limited imaging access isn’t purely a technology issue. It’s equally an economic one, driven by the high cost of equipment, the facility infrastructure required, and the specialized staff needed both to run the systems and to interpret the results.

Nanox presents the Nanox.ARC as one element of its wider initiative to bring advanced imaging into a broader range of healthcare settings. In the United States, the system is presently cleared only for adjunctive use alongside conventional radiography in adult patients for designated indications. In Europe, Nanox.ARC has obtained CE Mark certification, allowing commercialization, in accordance with the relevant country-specific regulations. 

Nanox continues to advance its imaging technology and develop additional capabilities aimed at expanding clinical applications and improving imaging workflows, subject to applicable regulatory requirements. However, expanding access to medical imaging goes beyond the imaging system itself. Healthcare providers also need solutions that support image management, interpretation, and access to radiology expertise.

Nanox addresses these needs through its broader imaging ecosystem. Nanox.CLOUD, the company’s cloud-based software platform, supports the management and storage of imaging data generated by Nanox devices. Through its subsidiary USARAD, Nanox also provides teleradiology services, while Nanox.MARKETPLACE offers remote access to radiology and cardiology experts. Together, these solutions support the company’s vision of providing an end-to-end imaging solution, extending from image acquisition to interpretation.

The company’s AI business adds another layer to this approach. Nanox.AI extends the value of routine medical imaging by leveraging AI to uncover additional clinical insights from CT scans already performed for other purposes. Its solutions help clinicians identify potentially overlooked imaging findings associated with chronic conditions, including cardiovascular disease, osteoporosis, and fatty liver disease. By transforming existing imaging data into actionable information for clinicians, Nanox.AI aims to support more informed clinical assessment and patient management.

Ultimately, Nanox’s strategy focuses on delivering an integrated, end-to-end medical imaging solution that connects image acquisition, management, interpretation, and AI-based analysis. By combining its digital tomosynthesis technology, cloud-based software, teleradiology services, and AI solutions, the company aims to improve clinical efficiency, expand access to medical imaging, and support earlier detection of chronic conditions. This integrated approach reflects Nanox’s broader vision of driving the transition toward more accessible, preventive healthcare.

For more information, visit the company’s website at https://www.nanox.vision.

NOTE TO INVESTORS: The latest news and updates relating to NNOX are available in the company’s newsroom at https://ibn.fm/NNOX

• Mobilicom provides integrated cybersecure hardware and software solutions for defense and commercial drones, robotics and autonomous systems.
• Its technologies are designed to support mission-critical communications, reliable connectivity and protection against electronic interference and cyber threats.
• The recent launch of the SwarmiX family expands Mobilicom’s portfolio with high-throughput mesh communications designed for coordinated drones and robotic fleets.

As defense organizations and commercial operators expand their use of unmanned systems, the technologies that keep these platforms connected, secure and operational are becoming increasingly important. Mobilicom (NASDAQ: MOB) addresses these needs through an integrated portfolio of cybersecurity, software and hardware designed for drones, robotics and other autonomous platforms operating in demanding environments.

The company primarily serves original equipment manufacturers (“OEMs”) developing unmanned platforms for applications where reliable communications and system resilience are essential. Its solutions address several core requirements of autonomous operations, including secure data transmission, robust connectivity and protection against cyber threats and electronic interference. By integrating its technologies at the platform level, Mobilicom aims to establish its solutions within systems deployed across defense and commercial markets.

Mobilicom’s portfolio spans cybersecurity software, communications and networking hardware, and operator control systems, enabling the company to address multiple operational requirements through a connected technology offering. This approach is particularly relevant in environments where communications disruptions or security vulnerabilities could compromise the effectiveness of unmanned systems.

The company reports deployments worldwide and a large customer base, including some of the world’s largest drone manufacturers. These relationships provide a foundation for potential expansion as OEMs develop new platforms and existing customers evaluate additional technologies. Nevertheless, translating this foundation into sustained growth will depend on factors such as new design wins, customer adoption, production volumes and the timing of defense procurement programs.

Mobilicom’s recent product introduction offers a closer look at how the company is extending its capabilities to meet the evolving demands of autonomous operations. The company introduced SwarmiX, a family of secure mesh communications solutions designed to support data-intensive missions involving coordinated drone and robotic fleets.

Expanding Mobilicom’s Secured Autonomy portfolio, SwarmiX is designed to deliver throughput of up to 1 gigabit per second, networking capabilities intended to connect hundreds of nodes, and multi-band spectrum agility across frequencies up to 7 GHz. The product family includes embedded modules for drones and robotics, alongside ruggedized tactical units designed for military personnel, vehicles and launch systems. Onboard computing capabilities are also intended to support cybersecurity functions directly on the module.

These capabilities address the growing complexity of coordinated unmanned operations, in which multiple platforms may need to exchange substantial amounts of information while operating in contested environments. Mobilicom introduced SwarmiX at the Association of the United States Army’s 2026 Annual Meeting and Exposition in Washington, D.C., bringing the technology before defense leaders and industry decisionmakers.

For Mobilicom, the opportunity extends beyond a single product launch. As drone and robotics manufacturers increasingly require communications technologies that combine high data throughput, dependable connectivity and embedded security, the company’s broader portfolio and established OEM relationships could create opportunities to expand its role within the unmanned systems market.

Ultimately, Mobilicom’s commercial progress will depend on its ability to convert these capabilities into broader adoption and measurable business results. Its global customer base and expanding technology portfolio provide a foundation to build upon, while future design wins, additional deployments and production growth will remain important indicators for investors evaluating the company’s trajectory.

For more information, visit the company’s website at Mobilicom.com.

NOTE TO INVESTORS: The latest news and updates relating to MOB are available in the company’s newsroom at https://ibn.fm/MOB

Disseminated on behalf of SuperQ Quantum Computing Inc. and may include paid advertisements.

• SuperQ Quantum Computing Inc. is developing an integrated quantum computing ecosystem that brings together software orchestration and modular hardware.
• Its Super OS(TM) operating system and Super Nova(TM) quantum computer are designed as complementary components of a broader full-stack approach to hybrid quantum computing.
• The strategy reflects a focus on connecting quantum and classical computing resources within flexible architectures intended to support enterprise, data center and defense applications.

As quantum computing advances toward practical applications, the opportunity extends beyond developing increasingly sophisticated algorithms. Bringing the technology into real-world environments also requires infrastructure capable of coordinating different computing resources, supporting specialized workloads and addressing deployment requirements.

SuperQ Quantum Computing Inc. (CSE: QBTQ) (OTCQB: QBTQF) is developing its technology around this broader challenge, pursuing a full-stack approach that pairs software with purpose-built quantum computing hardware. Through what it describes as its Full-Stack Quantum Supercomputing Matrix, the company is working to connect its operating system and hardware initiatives within a more integrated ecosystem.

At the center of this strategy is Super OS(TM), SuperQ’s operating system for hybrid quantum computing. Currently in development, the platform is designed to orchestrate classical computing resources, including central processing units (“CPUs”) and graphics processing units (“GPUs”), alongside quantum processing units (“QPUs”). Its architecture is intended to coordinate these resources through a unified execution layer, with a development roadmap progressing from API-driven solver orchestration toward more direct quantum hardware control.

Complementing this software initiative is Super Nova(TM), SuperQ’s modular quantum computer, also in development. Designed to run Super OS(TM) natively, the system is intended to bring quantum processors and classical computing infrastructure together within a modular architecture. The company’s stated design priorities include flexible hardware configurations, on-site deployment and greater control over sensitive computing environments.

Together, the two initiatives represent a wider vision than a software-only approach: developing the orchestration layer and the computing infrastructure that can work together to support hybrid workloads. Rather than treating software and hardware as separate offerings, SuperQ is pursuing an architecture in which each is designed to complement the other.

This approach could be relevant to organizations exploring quantum computing for complex optimization, financial modeling, scientific research and national security applications, where integration, data control and deployment flexibility can be important considerations.

As SuperQ continues developing Super OS(TM) and Super Nova(TM), its full-stack strategy places the relationship between software and hardware at the center of its efforts to advance practical hybrid quantum computing.

For more information, visit www.SuperQ.co.

NOTE TO INVESTORS: The latest news and updates relating to QBTQF are available in the company’s newsroom at ibn.fm/QBTQF

When Stocktwits gathered traders, executives, and financial creators at City Winery in New York City on October 7 for the programming day of Stocktoberfest presented by Tradr ETFs, the agenda was built around two forces the company sees defining how traders find an edge next: agentic trading and social relative strength. Across more than a dozen panels and fireside chats, those two ideas surfaced again and again, alongside sessions on the changing brokerage model, new trading products, and the growing pull of private markets.

Stocktwits Founder and CEO Howard Lindzon opened the programming with a keynote built around a live walkthrough of real historical crowd calls, revealed before the market knew how they would turn out. Lindzon followed with a fireside chat alongside Barry Ritholtz, Chairman and CIO of Ritholtz Wealth Management.

The agentic theme came into focus in the Agentic Trading & Investing panel, where Lindzon was joined by Jack Keating, CEO of Webull Tech US, and Nadia Asoyan, CFO of Alpaca. The session focused on how AI agents source signal and why community-generated sentiment data matters to them.

That shift reaches public companies too. The IR in the Age of AI panel, featuring Anne Marie Gianutsos, CCO of Stocktwits; Phil De Sousa, CFO of Voyager Technologies; and Paul Prager, Co-Founder and CEO of TeraWulf Inc., looked at how companies now communicate with both human investors and those investors’ AI agents.

Later in the day, Ted Seides of Capital Allocators joined Lindzon for a fireside chat on capital allocation in an AI world, and the closing panel, The World of Narratives & AI Trends, brought Ben Hunt and Michael Parekh to the stage to discuss why institutions increasingly treat the history of retail sentiment as a leading indicator.

The second theme, social relative strength, ran through sessions on how individual investors and creators build an advantage. In Social Arbitrage and the Democratization of Investing, Chris Camillo, Investor and Co-Host of DumbMoney.TV, sat down with Lindzon to explore how social arbitrage has given individual investors a real analytical edge over Wall Street’s traditional information advantages, what that edge is made of, and where it goes from here.

The Building an Audience the Algorithm Can’t Fake panel, with Katie Perry, CMO of zerohash; Douglas Boneparth, President of Bone Fide Wealth; Gautam Shah, CEO of Eras Capital; and Samantha LaDuc, Founder of LaDucTrading.com, brought leading retail voices together on building genuine communities and the kind of trust that cannot be manufactured.

The Brokerage 1.0 → 2.0 panel, with Marisa Ricciardi of The Ricciardi Group, Jack Newhouse of Rothschild Wealth Partners, and Hootie Rashidifard of Hash3, examined why data, sentiment, and distribution, rather than the trading interface itself, are becoming the next competitive moat. Lindzon continued the thread in a fireside chat on the future of brokerage with Anthony Denier, US CEO of Webull.

On the product side, the Leveraged & Inverse ETFs panel featured Michael Eschmann of REX Shares, Bilal Little of Direxion, and Matt Markiewicz of Tradr ETFs discussing tools that let high-conviction traders express a view without margin or options complexity. The Degenerate Economy panel, with Serge Kassardjian of 6th Man Ventures, Dan Kang of DeFi Development Corp., and Ethan Silver, took on why prediction markets and brokers are racing to become each other while crypto exchanges sit caught in the middle.

Private markets drew two sessions. Andrew Krochulick, COO of Nasdaq Private Market, joined Lindzon to discuss the rise of private markets and where they fit in modern portfolios, and Frederik Mijnhardt, CEO and Founder of Secfi, joined him for Valuation Madness: Making Sense of Late-Stage Privates and How to Profit.

For public companies at the smaller end of the market, the Shareholder Strategy for Emerging Tech & Small Caps panel, with Shannon Devine, Linda Montgomery of ZenaTech, Anupam Ghildyal of REalloys, and Katie Perry, focused on how small-cap companies can deliberately build and manage a retail shareholder base as a strategic asset.

The day concluded with closing remarks and a closing reception. Stocktoberfest 2026 was presented by Title Partner Tradr ETFs.

To learn more about Stocktoberfest and stay tuned for next year’s agenda, visit stocktoberfest.stocktwits.com.